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Abstract. 
 
The role of transmembrane 4 superfamily 
(TM4SF) proteins during muscle cell fusion has not 
been investigated previously. Here we show that the ap-
pearance of TM4SF protein, CD9, and the formation of 
CD9–
 
b
 
1 integrin complexes were both regulated in co-
ordination with murine C2C12 myoblast cell differenti-
ation. Also, anti-CD9 and anti-CD81 monoclonal anti-
bodies substantially inhibited and delayed conversion 
of C2C12 cells to elongated myotubes, without affecting 
muscle-speciﬁc protein expression. Studies of the hu-
man myoblast-derived RD sarcoma cell line further 
demonstrated that TM4SF proteins have a role during 
muscle cell fusion. Ectopic expression of CD9 caused a 
four- to eightfold increase in RD cell syncytia forma-
tion, whereas anti-CD9 and anti-CD81 antibodies 
markedly delayed RD syncytia formation. Finally, anti-
CD9 and anti-CD81 monoclonal antibodies triggered
apoptotic degeneration of C2C12 cell myotubes after 
they were formed. In summary, TM4SF proteins such as 
CD9 and CD81 appear to promote muscle cell fusion 
and support myotube maintenance.
Key words: TM4SF proteins • CD9 • CD81 • myo-
blast • myotube
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ROTEINS
 
 in the transmembrane 4 superfamily
(TM4SF),
 
1
 
 including CD9, CD37, CD53, CD63,
CD81, CD82, and CD151, have been functionally
implicated in cell proliferation, activation, motility, and tu-
mor cell metastasis. In the plasma membrane, TM4SF pro-
teins associate with each other and with other cell surface
molecules, including CD4, CD8, CD19, CD21, major his-
tocompatibility complex class I and II proteins, and inte-
grins (26, 30, 40, 73). In addition, some TM4SF proteins
may associate with cytoplasmic signaling molecules in-
cluding tyrosine phosphatase (12), phosphatidylinositol
4-kinase (7, 78), and protein kinase C (PKC) (Zhang, X.,
and M.E. Hemler, manuscript submitted for publication).
Through TM4SF proteins, these intracellular signaling
molecules may be linked to the extracellular domains of
integrins (24).
The CD81 protein may be a receptor for hepatitis C vi-
rus (54). Also, several TM4SF proteins may participate in
virus-induced cell fusion. Antibodies against CD81 and
CD82 inhibited human T cell leukemia virus type 1
(HTLV-1) but not HIV-1–induced syncytia formation
(20). Overexpression of CD9 enhanced the susceptibility
of cells to feline immunodeficiency virus (FIV) and canine
distemper virus (39, 72), leading to elevated syncytia for-
mation. Antibodies against CD9 reduced syncytia forma-
tion and/or virus production (17, 39, 72). Because the CD9
protein does not appear to directly bind to virus (39), it
may act as a membrane fusion cofactor, rather than a pri-
mary virus receptor. Also, CD9 may play a role in the gen-
eration of multinucleate osteoclasts (64). From these re-
sults, we hypothesize that TM4SF proteins may play a
general role in cell fusion events.
To extend this hypothesis, here we investigate the roles
played by TM4SF proteins CD9 and CD81 in myogenic
cell fusion. Integrins have been suggested previously to
play a role during myogenesis (47, 57), as have other cell
surface proteins including vascular cell adhesion molecule
(VCAM)-1 (57), neural cell adhesion molecule (N-CAM)
(18, 35), N-cadherin (36, 45), M-cadherin (79), meltrin
(74), proteoglycans (56), and CDO (a protein with five Ig
and three FNIII repeats) (34). However, a role for TM4SF
proteins has not been demonstrated previously, and in
fact, there have been few if any studies of TM4SF proteins
on myoblasts or during myogenesis.
Here we have used the murine myoblast line C2C12 and
the human rhabdomyosarcoma cell line RD to analyze the
role of CD9 and CD81 during muscle cell fusion. CD9 and
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CD81 were chosen for study because they are both promi-
nently expressed on skeletal muscle (50, 58) and on mu-
rine myoblast C2C12 cells (see below), and because mAbs
to murine CD9 and CD81 are available. Our results sug-
gest that CD9 and CD81 may regulate fusion of both
C2C12 and RD cells, and may also regulate myotube
maintenance.
 
Materials and Methods
 
Cell Lines
 
The human rhabdomyosarcoma line RD was obtained from American
Type Cell Collection. RD cells were transfected with integrin 
 
a
 
3 cDNA to
yield RD-A3 as described previously (71). RD-C9-1 and RD-C9-2 are sta-
ble, unsorted lines independently derived by transfecting RD cells with
full-length CD9 cDNA (generated by reverse transcriptase PCR) that was
cloned into the expression plasmid pZeoSV (Invitrogen). Likewise, RD-
A3C9-1 and RD-A3C9-2 are independently prepared stable transfectants
derived from RD-A3 cells. All RD cells and transfectants were cultured in
DME supplemented with 10% FCS. To induce differentiation and syncy-
tia formation, subconfluent RD cells were cultured in 2% FCS. The
mouse myogenic cell line C2C12 (8) was obtained from American Type
Cell Collection and maintained in DME supplemented with 20% FCS
(growth medium). To induce differentiation of confluent C2C12 cells,
growth medium was replaced with DME containing 2% horse serum (dif-
ferentiation medium) (57). To avoid loss of fusion competence, C2C12
cells were passaged only a few times before use.
 
Antibodies
 
Rat anti–mouse mAbs KMC8, anti-CD9; R1-2, antiintegrin 
 
a
 
4; MFR5, an-
tiintegrin 
 
a
 
5; KMI6, antiintegrin 
 
b
 
1; KM114, anti-CD44; R35-95, rat
IgG2a negative control antibody; and hamster anti–mouse mAbs, HM
 
b
 
1-1
and Ha2/5, antiintegrin 
 
b
 
1, were all obtained from PharMingen. Hamster
anti–mouse CD81 mAb 2F7 was purchased from Southern Biotechnology.
Rat anti–mouse mAb CY8.2, antiintegrin 
 
a
 
7, was a gift from Dr. Randall
Kramer, University of California, San Francisco, San Francisco, CA. Rab-
bit polyclonal antibody against the integrin 
 
a
 
3A cytoplasmic tail was pro-
vided by Dr. J.A. McDonald (Mayo Clinic, Scottsdale, AZ). Mouse anti–
human N-CAM mAb, NCAM-OB11; anti–N-cadherin mAb, GC-4; and
anti-pan cadherin cytoplasmic tail mAb, CH-19, all of which cross-react
with mouse, were purchased from Sigma Chemical Co. Mouse mAbs MY-
32, anti–myosin heavy chain (MHC); and DE-U-10, antidesmin, were also
obtained from Sigma Chemical Co., and mouse antiactin mAb, C4, was
purchased from ICN Biomedicals, Inc. Mouse anti–human mAbs were
against integrin 
 
a
 
5, A5-PUJ2 (55); CD9, BU16 (Biodesign International),
DU-ALL-1 (Sigma Chemical Co.), C9-BB (6); and CD81, M38 (20).
 
Assay for C2C12 Myotube Formation
 
C2C12 cells were plated onto a 96-well tissue culture plate at 20,000 cells/
well and cultured in growth medium. At confluence, growth medium was
replaced by differentiation medium, in the presence of various mAbs.
Numbers of myotubes in four independent 2.6-mm
 
2
 
 fields were scored by
microscopy as described (68). Elongated, glossy myotubes were easily dis-
tinguished from unfused myoblasts (see Fig. 4). In some experiments,
numbers of myotubes per well that were longer than 250 
 
m
 
m were deter-
mined using the program Scion Image 1.60 (Scion Corp.), to acquire and
analyze computer images from an Axiovert 135 microscope (Carl Zeiss)
(as described in detail elsewhere; Stipp, C.S., and M.E. Hemler, manu-
script submitted for publication).
 
Apoptosis Analysis
 
C2C12 cells were plated onto an 8-well chamber Permanox slide (Nunc)
and precoated with mouse laminin (GIBCO BRL). Confluent cells were
cultured in differentiation medium (with or without anti-TM4SF antibod-
ies) for 6 d and then fixed with 2% paraformaldehyde and permeabilized
with 0.1% Triton X-100, 0.1% sodium citrate. Nuclei of apoptotic cells
were stained by terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP nick end-labeling (TUNEL) (21), using In Situ Cell Death Detec-
tion Kit (Boehringer Mannheim) according to the manufacturer’s in-
structions. Immunofluorescence was analyzed using an Axioscop (Carl
Zeiss).
For DNA ladder analyses, C2C12 cells were cultured for 6 d in differ-
entiation medium, and then myotubes were detached from mixed myo-
blast/myotube cultures by treatment with 0.01% trypsin, 0.004% EDTA
for 15 min as described previously (5). DNAs were extracted using the
Apoptotic DNA Ladder Kit (Boehringer Mannheim) according to the
manufacturer’s instructions, electrophoresed in 2% agarose gel, and
stained with 0.5 
 
m
 
g/ml ethidium bromide.
 
Immunoprecipitation
 
C2C12 cells were lysed in lysis buffer (1% Brij 96 or Brij 99, 25 mM
Hepes, pH 7.5, 150 mM NaCl, 5 mM MgCl
 
2
 
, 2 mM PMSF, 10 
 
m
 
g/ml aproti-
nin, 10 
 
m
 
g/ml leupeptin) for 1 h at 4
 
8
 
C. Insoluble materials were pelleted
at 12,000 rpm for 10 min, and the cell lysates were precleared twice by in-
cubation with protein G (Amersham Pharmacia Biotech) for 30 min at
4
 
8
 
C. Immune complexes were formed by addition of mAbs and collected
onto protein G beads, followed by four washes with immunoprecipitation
buffer. After elution from beads with Laemmli sample buffer, proteins
were separated on SDS-PAGE, transferred to nitrocellulose membranes,
and blotted with biotinylated antibody followed by peroxidase-conjugated
ExtraAvidin (Sigma Chemical Co.) and visualized with Renaissance
Chemiluminescent Reagents (DuPont).
 
Immunoblotting and Flow Cytometry
 
Whole cell lysates were separated by SDS-PAGE, transferred to nitrocel-
lulose membranes, and then preblotted with PBS containing 0.05%
Tween 20 and 3–5% nonfat dry milk. Proteins were then sequentially im-
munoblotted with primary antibody followed by peroxidase-conjugated
secondary antibody, and visualized with Renaissance Chemiluminescent
Reagents.
For flow cytometry, cells were incubated with negative control mAb or
specific mAb, washed three times, and then incubated with FITC-conju-
gated goat anti–mouse Ig. Stained cells were analyzed using a FACScan™
(Becton Dickinson). Fluorescence with negative control mAb was sub-
tracted to give specific mean fluorescence intensity (MFI) units.
 
Results
 
Modulation of CD9 Levels and Integrin Association 
during C2C12 Myogenesis
 
To evaluate the role of a representative TM4SF protein on
myogenic cells, we monitored CD9 expression on mouse
C2C12 cells undergoing myogenic cell differentiation. At
confluence, C2C12 cells begin fusing into myotubes and
express muscle-specific proteins under the control of mus-
cle-specific transcription factors, including MyoD, myoge-
nin, Myf-5, and MRF4 (38). This differentiation is acceler-
ated by medium containing low levels of serum. The level
of CD9 protein was upregulated as C2C12 cells ap-
proached confluence, and reached a peak at 
 
z
 
1 d after in-
cubation in differentiation medium (Fig. 1, A and B).
In contrast, muscle-specific proteins desmin and MHC
were upregulated at a later stage. Control antiactin blots
showed comparable amounts of protein loaded on each
lane (Fig. 1, A and B).
After 1 d of C2C12 myoblast differentiation, TM4SF
proteins CD9 and CD81 could be coimmunoprecipitated
with several different 
 
b
 
1 integrins, including 
 
a
 
3
 
b
 
1, 
 
a
 
5
 
b
 
1,
and 
 
a
 
7
 
b
 
1 (not shown). Although there have been many
reports of constitutive TM4SF–integrin association (for re-
view see references 24 and 26), there has been little evidence
that such complexes can be regulated. Here we show that
formation of integrin–CD9 complexes is highly regulated,
particularly in the early phase of C2C12 differentiation
(Fig. 2 A). During subconfluent growth, relatively little 
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CD9 was detected in a 
 
b
 
1 immunoprecipitation (Fig. 2 A,
lane a), and little 
 
b
 
1 was present in a CD9 immunoprecipi-
tation (Fig. 2 A, lane g), even though 
 
b
 
1 (Fig. 2 A, lane a)
and CD9 (Fig. 2 A, lane g) were clearly present. However,
as cells reached confluence and began to differentiate,
complex formation was clearly upregulated. 
 
b
 
1 integrin–
CD9 complexes reached a maximum at 
 
z
 
1 d after culture
in differentiation medium (Fig. 2 A, lanes a–d and g–j).
Complex formation was sustained, or decreased slightly,
during the later stages of differentiation (Fig. 2 A, lanes
d–f and j–l). Densitometric quantitation of immunoblotted
 
b
 
1 and CD9 levels (Fig. 2 C) confirmed a marked increase
in the ratio of 
 
b
 
1-associated CD9 relative to total immuno-
precipitated 
 
b
 
1, with the peak ratio (
 
r
 
 
 
5 
 
2.0) occurring af-
ter 1 d of differentiation. Likewise, there was an increase
Figure 1. Modulation of
CD9 during C2C12 differen-
tiation. C2C12 cells were
monitored as they ap-
proached confluence, and
then culture medium was re-
placed with differentiation
medium (DM). (A) At the
indicated stages, cells were
lysed with Brij 96 lysis buffer,
and equal amounts of total
cell proteins were separated
on SDS-PAGE, transferred
to nitrocellulose membrane,
and then blotted with anti-
CD9 (KMC8), anti-MHC
(MY-32), antidesmin (DE-
U-10), and antiactin (C4)
mAbs. (B) For quantitation,
blots were analyzed on a
FluorImager (Molecular Dy-
namics) using ImageQuant
software.
Figure 2. Regulation of integrin–TM4SF complex formation. (A)
C2C12 myoblasts were cultured to form myotubes, and cells were
lysed in 1% Brij 99 at the indicated stages. Each cell lysate was
used for immunoprecipitation (IP) with antiintegrin b1 and anti-
CD9 mAbs. After transfer of proteins, membranes were blotted
with biotinylated antiintegrin b1 and biotinylated anti-CD9
mAbs in the same experiment. More sample was loaded in lanes
g and h to compensate for diminished CD9 expression. (B) Con-
fluent C2C12 myoblasts were lysed and immunoprecipitations
were performed using a pan-cadherin mAb (CH-19), and mAbs
to N-CAM, CD9, CD81, and integrin b1. Proteins were blotted
with biotinylated antiintegrin b1 mAb (KMI6) and pan cadherin
mAb (CH-19). (C) For quantitation, blots were analyzed on a
FluorImager. Ratios represent coprecipitated CD9 levels/b1 lev-
els (circles, data from A, lanes a–f) and coprecipitated b1 levels/
CD9 levels (squares, data from A, lanes g–l). 
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in CD9-associated 
 
b
 
1 relative to total immunoprecipitated
CD9, again with the peak ratio (
 
r
 
 
 
5 
 
0.5) occurring after 1 d
of differentiation. Notably, these peak ratios were 7–15-
fold greater than ratios obtained when cells were 40%
confluent. In another experiment, immunoprecipitation of
CD81 yielded associated 
 
b
 
1 and CD9 proteins, with peak
association again occurring at 
 
z
 
1 d after differentiation
(data not shown).
In a control experiment, after 1 d of differentiation (Fig.
2 B) mature integrin 
 
b
 
1 protein was present in immuno-
precipitates of CD9 (Fig. 2 B, lane d) or CD81 (Fig. 2 B,
lane e), but not cadherin (Fig. 2 B, lane b) or N-CAM.
Both mature and immature precursor forms of 
 
b
 
1 were
present in C2C12 cell lysate (Fig. 2 B, lane a) and in a 
 
b
 
1
immunoprecipitate (Fig. 2 B, lane f).
 
Effects of Anti-TM4SF and Antiintegrin mAbs on 
C2C12 Myotube Formation and Maintenance 
 
We used mAbs KMC8 and 2F7 to determine (by flow cy-
tometry) that TM4SF proteins CD9 and CD81 were both
present on 100% of C2C12 cells, at levels 
 
z
 
100–1,000-fold
above background (data not shown). The addition of
mAbs to either CD9 or CD81 caused a marked delay in
the formation of myotubes, and both mAbs together
showed an additive inhibitory effect, as seen in three dif-
ferent experiments (Fig. 3, A, C, and D). A photo illustrat-
ing the delay caused by anti-CD9 plus anti-CD81 mAb at
day 3 is shown in Fig. 4 A. In contrast to the anti-TM4SF
antibodies, antiintegrin anti-
 
a
 
4, anti-
 
a
 
5, and anti-
 
b
 
1 anti-
bodies did not delay myotube formation. Likewise, no de-
Figure 3. Anti-TM4SF
mAbs affect C2C12 myo-
tube formation. C2C12 myo-
blasts were cultured in a 96-
well tissue culture plate. (A,
C, and D) When cells were
confluent (day 0), medium
was replaced with differenti-
ation medium containing 10
mg/ml of various mAbs. In B,
mAbs were not added until
5 d after medium replace-
ment. mAbs used were
KM114, anti-CD44; KMC8,
anti-CD9; 2F7, anti-CD81;
R1-2, antiintegrin a4; MFR5,
antiintegrin  a5; Ha2/5, anti-
integrin b1; and R35-95, neg-
ative control. In several
wells, two mAbs (10 mg/ml
for each) were combined.
Each data point represents
the mean number of myo-
tubes from four determina-
tions (from independent 2.6-
mm2 fields) 6SD. Flow
cytometry and immunopre-
cipitation showed that CD9,
CD81, CD44, and integrin a5
were all expressed compara-
bly in confluent C2C12 myo-
blasts, whereas integrin a4
was expressed only in C2C12
myotubes (data not shown).
Also, all antibodies (except
R35-95) used here and in Fig.
4 were shown previously to
inhibit cell functions in vitro.
For example, KM114 (refer-
ence 48), R1-2 (reference
19), MFR5 (reference 23),
and Ha2/5 (reference 46)
inhibited cell adhesion,
whereas KMC8 and 2F7 in-
hibited myeloid and T cell
development, respectively
(references 10, 53). 
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lay was caused by anti-CD44 or anti-CD44 plus anti-
 
a
 
5 to-
gether (Fig. 4 A and Fig. 3, C and D). However, anti-
 
a
 
5
and anti-
 
b
 
1 mAbs did cause myotubes at day 3 to be sig-
nificantly shorter than myotubes treated with control
mAb, anti-CD44 mAb, or anti-
 
a
 
4 mAb (Fig. 4 A). mAbs
to other integrin subunits were not tested for the following
reasons: an anti-murine 
 
a
 
3 mAb is not yet available, the
anti-
 
a
 
7 mAb was not available in sufficient quantity, and
the 
 
a
 
6 subunit is only weakly expressed on C2C12 cells.
Anti-CD9 and anti-CD81 antibodies, either alone or in
combination, had no effect on myoblast proliferation as
C2C12 cells grew to confluence in growth medium over a
5-d period (data not shown). Thus, anti-TM4SF antibody
effects on myotube formation are not an indirect conse-
quence of inhibition of myoblast proliferation.
Anti-CD9 and anti-CD81 mAbs not only caused a delay
in myotube formation, but also accelerated myotube de-
generation (Fig. 3). Specific examples of myotube degra-
dation at day 10 are shown in Fig. 4 B. Again, the effects of
anti-CD9 and anti-CD81 mAb were additive (Fig. 3 and
Fig. 4 B). Again, myotube maintenance was not affected
by control mAb, anti-
 
a
 
4, anti-
 
a
 
5, anti-CD44, or anti-
 
b
 
1
mAbs (Fig. 3 and Fig. 4 B). In Fig. 3 B, mAbs were not
added to cultures until day 5, when peak numbers of myo-
tubes were already formed. Nonetheless, in subsequent
days the numbers of myotubes again were diminished
upon addition of anti-TM4SF mAb, with the effects of
anti-CD9 and anti-CD81 mAbs being additive. This result
excludes the possibility that delayed myotube formation is
responsible for the subsequent degeneration of myotubes.
Figure 4. Delay of myotube
formation (A) and early de-
generation of myotubes (B)
in the presence of anti-TM4
mAbs. C2C12 cells were dif-
ferentiated in the presence of
10 mg/ml of various mAbs as
in the legend to Fig. 3. Cell
images at day 3 (A) and day
10 (B) were saved using a
light microscope and the
computer program, Scion
Image 1.60. Bars, 250 mm. 
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Effects of an anti-CD9 mAb (KMC8) were even more
dramatically obvious when elongated myotubes (
 
.
 
250 
 
m
 
m)
were analyzed rather than total myotubes. As shown in
Fig. 5, 
 
z
 
50% fewer elongated myotubes were formed in
the presence of 20 
 
m
 
g/ml KMC8 at day 3. By day 5, the in-
hibitory effect was less pronounced, with 
 
z
 
25% fewer
elongated myotubes being formed. The most dramatic ef-
fect of mAb KMC8 was seen after maximal elongated myo-
tube formation had already occurred (days 6–8). For ex-
ample, at day 8, 
 
z
 
90% fewer myotubes were maintained
when 10–20 
 
m
 
g/ml KMC8 was present (Fig. 5). These anti-
CD9 mAb effects were clearly dose dependent.
To assess antibody effects on myotube attachment,
C2C12 myoblasts were allowed to differentiate into myo-
tubes in the presence of antibodies for 5 d, and then de-
tached myotubes were removed by washing. Counting of
myotubes present before and after washing (in quadrupli-
cate) revealed that myotube detachment was relatively un-
affected by antibody incubation (no antibody, 29% de-
tachment; control IgG, 27% detachment; anti-
 
a
 
4, 32%
detachment; anti-
 
a
 
5, 34% detachment; anti-CD44, 33% de-
tachment; anti-CD9, 30% detachment; anti-CD81, 31%
detachment; anti-CD9
 
 
 
plus anti-CD81, 18% detachment).
Thus, failure to maintain myotubes did not appear to re-
sult from direct promotion of detachment by anti-CD9 or
anti-CD81 mAbs. In another experiment, neither anti-
CD9 nor anti-CD81 mAb had any effect on confluent
C2C12 myoblast cell adhesion to tissue culture plastic, or
to surfaces coated with fibronectin or mouse laminin 1.
Likewise, these antibodies had no consistent effect on ei-
ther random C2C12 cell motility or transwell haptotaxis
towards fibronectin or laminin (data not shown). In a sep-
arate experiment, a culture of confluent myoblasts was dis-
rupted by scratching with a plastic tip. Again, anti-CD9
and anti-CD81 antibodies had no effect on the rate of
myoblast migration into the vacated area, or on the align-
ment of myotubes in that area.
 
Anti-TM4SF mAbs Do Not Delay MHC or
Desmin Expression
 
A previous report demonstrated that antiintegrin 
 
b
 
1 mAb,
CSAT, inhibited both morphological differentiation (myo-
tube formation), and biochemical differentiation (mero-
myosin expression) in chicken embryo myoblasts (47).
Here we demonstrate that a combination of anti-TM4SF
CD9 and CD81 mAb did not alter biochemical differentia-
tion of C2C12 cells (Fig. 6), marked by the appearance of
either MHC or desmin. In contrast, an anti-
 
b
 
1 mAb did
substantially lower the appearance of MHC, consistent
with previous anti-
 
b
 
1 mAb effects on biochemical differ-
entiation (47). Control antiactin immunoblots showed that
equal amounts of protein were loaded in each lane.
Figure 5. Dose-dependent inhibition of elongated myotube for-
mation by anti-CD9 mAb. Confluent C2C12 cells were incubated
with differentiation media (day 0) in the presence of various con-
centrations of anti-CD9 mAb (KMC8). Numbers of myotubes
longer than 250 mm were determined by counting entire wells
(z38 mm2) of a 96-well plate. Thus, even though only long myo-
tubes were counted, larger numbers are obtained than in Fig. 3,
in which fields of 2.6 mm2 were analyzed. Myotube length was
determined using the program Scion Image 1.60. For each point,
n 5 1.
Figure 6. C2C12 cell expression of MHC and desmin is not af-
fected by anti-TM4SF mAbs. C2C12 cells were differentiated in
the presence of 10 mg/ml of control, antiintegrin b1, or anti-CD9 1
anti-CD81 mAbs. Cells were lysed with Brij 96 lysis buffer 0–4 d
after culture in differentiation medium (DM), and whole cell ly-
sates were fractionated on SDS-PAGE. Proteins were trans-
ferred to a nitrocellulose membrane and then blotted with anti-
MHC, antidesmin, and antiactin mAbs. 
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Anti-TM4SF mAbs Cause Early Apoptosis of
C2C12 Myotubes
Anti-CD9 and anti-CD81 mAbs induced early degenera-
tion of C2C12 myotubes (Figs. 3–5). Some of these myo-
tubes showed cellular blebs (data not shown), which is sug-
gestive of apoptosis. Thus, we used the TUNEL method to
confirm whether degenerating myotubes were apoptotic.
Fluorescein-labeled UTP was incorporated into nuclei of
degenerating myotubes after 6 d in the presence of anti-
CD9 or anti-CD81 mAb (Fig. 7 A, right panels). In con-
trast, myotube nuclei were not stained when either control
mAb or no mAb was present. Also, no unfused myoblasts
were stained in any of the cultures. Because only a fraction
of the total myotubes appeared to undergo apoptosis, we
did not expect to see a strong DNA laddering effect.
Nonetheless, we separated myotubes from unfused myo-
blasts, extracted DNA, and studied apoptosis-associated
internucleosomal fragmentation by electrophoresis (Fig. 7
B). Albeit at a low level, DNA laddering was evident in
myotubes cultured in the presence of anti-CD9 or anti-
CD81 mAb (Fig. 7 B, lanes c and d). In contrast, the con-
trol lane did not show DNA laddering although the same
amount of DNA was loaded (Fig. 7 B, lane b).
In additional studies, apoptosis in a mixed myotube/
Figure 7. Induction of C2C12 myotube apoptosis by anti-TM4SF mAbs. (A) C2C12 cells were cultured in differentiation medium for
6 d on a slide precoated with mouse laminin in the absence or presence of control, anti-CD9, and anti-CD81 mAbs. Cells were then fixed
(2% paraformaldehyde) and permeabilized (0.1% Triton X-100), and nuclei of apoptotic cells were stained by TUNEL. Cells were visu-
alized using a Zeiss Axioscop microscope, and phase–contrast (left panels) and epifluorescent (right panels) images were obtained. Bar,
50 mm. (B) C2C12 cells were again differentiated for 6 d in the absence or presence of anti-TM4SF mAbs. Then, myotubes were enzy-
matically separated from unfused myoblasts, and DNAs were extracted, electrophoresed in 2% agarose gel, and stained with ethidium
bromide. Lane a shows a control 100-bp DNA ladder.The Journal of Cell Biology, Volume 146, 1999 900
myoblast preparation was determined by measuring his-
tone-associated DNA fragments (Cell Death Detection
ELISAPLUS Kit; Boehringer Mannheim). After only 4 d
of differentiation, anti-CD9 and anti-CD81 mAb each
yielded  z1.1–1.2-fold enhancement of apoptosis, and both
antibodies together yielded only z1.5-fold enhancement
of apoptosis. However, after 6 d of differentiation, anti-
CD9 and anti-CD81 mAb each yielded z1.5-fold enhance-
ment of apoptosis (compared with control mAb), and both
antibodies together yielded z3-fold enhancement of apop-
tosis. Together these results suggest that anti-TM4SF
mAbs induce early apoptosis of C2C12 myotubes, but not
unfused myoblasts.
CD9 Promotes RD Cell Syncytia Formation
For further evaluation of TM4SF protein function in mus-
cle-derived cells, we transfected CD9 into the human myo-
blast-derived RD sarcoma cell line. Although confluent
RD cells continue growing, they constitutively express
myogenic transcription factors, and undergo a limited and
abortive myogenic differentiation (11, 28, 65). Here we an-
alyzed RD cell transfectants as they became confluent af-
ter z6 d in 2% FCS. An RD cell line overexpressing CD9
(RD-C9-2) became substantially more multinucleate than
untransfected RD (Fig. 8, left panels). Likewise, RD cells
transfected with CD9 plus integrin a3 subunit (RD-A3C9)
became substantially more multinucleate than RD cells
transfected with a3 alone (RD-A3; Fig. 8, right panels).
Some of these multinucleate cells were myotubes, but
most of them were apolar, giant cells that resemble virus-
induced syncytia (Fig. 8, bottom panels). Using time-lapse
video microscopy, we confirmed fusion between a multi-
nucleate giant cell and a mononucleate cell (data not
shown). Despite differences in syncytia formation, all of
the RD transfectants proliferated at essentially the same
rate as RD cells.
Quantitation revealed that two distinct RD lines overex-
pressing CD9 (RD-C9-1, RD-C9-2) formed approximately
fourfold more syncytia than untransfected, mock-trans-
fected (RD-Z), or control transfected (RD-A3) cells (Fig.
9 A). Also, two distinct RD lines expressing both a3 inte-
grin and CD9 (RD-A3C9-1, RD-A3C9-2) showed approx-
imately eightfold more syncytia than control RD cells, in-
cluding RD-A3 cells expressing a3 alone (Fig. 9 A). CD81
overexpression studies were not carried out because CD81
is already highly expressed on RD cells. Effects of TM4SF
overexpression on longer-term syncytia maintenance could
not be determined, as syncytia became obscured and dis-
placed by unfused tumor cells that were continually grow-
ing and preferentially adherent. In a separate experiment,
CD9-transfected fibrosarcoma cells (HT1080-CD9) (6)
were cultured for 5–8 d as they became confluent in 2%
FCS. No syncytia were observed for this cell line during
this time.
Anti-CD9 mAbs, BU16 and DU-ALL-1 (Fig. 9 B), sub-
stantially delayed the appearance of RD-C9-1 cell syncy-
tia. However, no delaying effect was seen with another
anti-CD9 mAb, C9/BB, which recognizes a different CD9
epitope. An anti-CD81 mAb, M38, also delayed syncytia
formation, whereas a control antiintegrin a5 mAb, A5-
PUJ2, did not affect syncytia formation.
Discussion
Despite the strong expression of CD9, CD81, and other
TM4SF proteins on skeletal muscle (50, 58), the role of
TM4SF proteins during myogenesis had not been studied
previously. Here we found that CD9 and CD81 are also
abundant on murine myoblast C2C12 cells, and we pro-
vide strong evidence for the involvement of at least two
TM4SF proteins (CD9 and CD81) during myoblast differ-
entiation. First, CD9 expression was upregulated during
the early phase of myogenic differentiation of murine
C2C12 cells. Second, anti-CD9 and anti-CD81 antibodies
substantially delayed fusion of C2C12 myoblast cells and
RD rhabdomyosarcoma cells. Third, CD9 overexpression
promoted cell fusion in four independently transfected
myoblast-derived RD cell lines.
Possible Mechanisms for TM4SF Protein Contributions 
to Myoblast Fusion
In contrast to muscle-specific proteins MHC and desmin,
CD9 expression was upregulated at a much earlier stage of
myoblast differentiation. In addition, anti-TM4SF anti-
bodies caused a delay in cell fusion without altering bio-
chemical differentiation of C2C12 cells (as evidenced by a
lack of effect on MHC or desmin expression). Thus, CD9
expression appears neither to participate in myogenic
transcription factor regulation of other proteins, nor to be
regulated by myogenic transcription factors. Also, the de-
lay in fusion seen here was not due to altered myoblast
proliferation, although antibodies to CD9 and CD81 have
Figure 8. Syncytia formation by RD transfectants. RD transfec-
tants (2 3 104) were plated into wells of a 96-well plate and cul-
tured in DME containing 2% FCS for 6 d until confluence. Cells
were visualized using Wright stain, and the program Scion Image
1.60 was used to acquire and analyze computer images from a
Zeiss Axiovert 135 microscope. Levels of CD9, in MFI units,
were 31 (RD), 10 (RD-A3), 1122 (RD-C9-2), and 910 (RD-
A3C9-1). Levels of a3 were 10 (RD), 67 (RD-A3), 11 (RD-C9-
2), and 66 (RD-A3C9-1). Bar, 250 mm.Tachibana and Hemler TM4SF Proteins CD9 and CD81 in Myogenesis 901
been reported to affect lymphocyte proliferation (62, 67).
Likewise, delayed fusion did not appear to arise from pro-
motion of cell detachment, inhibition of attachment, or
altered C2C12 cell migration or alignment. Instead, we
hypothesize that TM4SF proteins may delay or inhibit
myogenesis at an early stage, by a mechanism that may di-
rectly influence cell fusion.
Fusion was delayed in two different cell types, upon
treatment with three different anti-CD9 mAbs and two
different anti-CD81 mAbs. In addition, RD cell fusion was
promoted upon transfection of CD9. These results are
consistent with TM4SF proteins contributing to fusion,
perhaps by engaging in protein–protein interactions with
each other, or with other proteins. In this regard, TM4SF
proteins are reported to associate laterally with many
other cell surface proteins (24, 40, 61, 73). At present,
there is no evidence for TM4SF proteins having counter-
receptors that would participate in cell–cell interactions.
Although CD9 (and a3 integrin) promoted fusion in RD
cells, no syncytia formation was seen in CD9-transfected
HT1080 fibrosarcoma cells, which are known to contain
CD9–a3b1 integrin complexes (6). Thus, CD9 and a3 inte-
grin by themselves are not sufficient to promote fusion, as
the rhabdomyosarcoma RD cells must contain specific
proteins or other factors required for cell fusion.
The TM4SF effects on myoblast fusion shown here are
reminiscent of anti-TM4SF antibody effects and CD9
overexpression effects on virus-induced syncytia forma-
tion (17, 20, 39, 72). For example, the delay in myoblast fu-
sion seen here with anti-CD81 and anti-CD9 antibodies
could be mechanistically related to the delay in feline im-
munodeficiency virus (FIV) production caused by anti-
CD9 mAb (17). Also, a more distantly related TM4SF
protein called peripherin/rds was reported to promote fu-
sion of lipid vesicles in vitro (9). Besides directly contribut-
ing to fusion through potential protein–protein interac-
tions, TM4SF proteins might also contribute to myoblast
fusion by regulating cellular signaling. In this regard, CD9
and CD81 associate with phosphatidylinositol 4-kinase (7)
and with PKCa and PKCbII (Zhang, X., and M. Hemler,
manuscript in preparation). Consistent with this, PKC
plays a key role in myoblast fusion (16), and PKCa is
present in both myoblasts and myotubes (29).
TM4SF Proteins and Integrins
We found that CD9 on C2C12 cells associates with various
b1 integrins, including a3b1,  a5b1, and a7b1 and that
CD9 associated with a3b1 on a3-transfected RD cells.
These results are consistent with integrin–TM4SF protein
associations seen on many other cell lines (6, 22, 24, 26, 33,
40, 51, 52). Importantly, we have provided firm evidence
for the upregulation of CD9–b1 integrin complexes in co-
ordination with the onset of myoblast differentiation. As
far as we know, there have been few if any prior demon-
strations of physiologically relevant integrin–TM4SF com-
plex regulation. The regulated formation of TM4SF–inte-
grin complexes suggests that they could play a role during
myogenesis. Indeed, even though a3 integrin alone did not
effect RD cell fusion, it potentiated the effects of CD9,
such that twice as many syncytia were formed. Possibly, in-
tegrin expression could contribute to myoblast fusion by
altering the distribution and/or signaling functions of CD9
in a way that does not affect integrin-dependent cell adhe-
Figure 9. Quantitation and in-
hibition of RD cell syncytia
formation. (A) RD trans-
fectants were cultured, and
then syncytia (with more than
three nuclei) were counted
daily, until confluence. Maxi-
mal numbers of syncytia for
each transfectant are shown.
RD-Z corresponds to mock
(pZeoSV)-transfected RD.
Coimmunoprecipitation experi-
ments confirmed that integrin
a3b1 associated with CD9 in
the RD-A3C9 transfectants
(data not shown). RD-C9-1
and RD-C9-2 were indepen-
dently derived from RD cells;
RD-A3C9-1 and RD-A3C9-2
were independently derived
from RD-A3 cells. (B) RD-
C9-1 cells were cultured for
6 d in the absence or presence
of mAb to integrin a5 (A5-
PUJ2), CD9 (BU16, DU-
ALL-1, and C9-BB), or CD81 (M38). Similar results were obtained in multiple additional experiments using both RD-C9-1 and RD-C9-2
cells (data not shown). The BU16 (39) and M38 (20) antibodies were shown previously to inhibit virus-induced syncytia. Notably, the
levels of a5 (z60 MFI units) and CD81 (z300 MFI units) were essentially unchanged in the various RD cell transfectants. For each re-
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sion or motility. The a3b1 integrin is absent from adult
striated muscle, but is variably present in fetal skeletal
muscle (4, 43, 44), whereas the a7b1 and a5b1 integrins
are prominent on myoblasts and developed skeletal mus-
cle (14, 37, 59, 60).
Although integrins may modulate TM4SF protein con-
tributions during myogenesis, there are several critical dif-
ferences between the roles of TM4SF proteins and inte-
grins. First, anti-CD9 and anti-CD81 antibodies caused a
delay in myoblast fusion, whereas antiintegrin a4, a5, and
b1 antibodies did not cause a delay in the appearance of
the peak number of myotubes. Second, anti-a5 and anti-
b1 antibodies caused myotubes at day 3 to be significantly
shortened, but anti-CD9 and anti-CD81 did not have this
effect. Third, anti-CD9 and anti-CD81 mAbs had no effect
on biochemical differentiation of C2C12 cells (defined by
MHC or desmin appearance), whereas an anti-b1 mAb
did markedly inhibit MHC appearance, consistent with
previous anti-b1 mAb effects on biochemical differentia-
tion in chicken embryo myoblasts (47). Fourth, antiinte-
grin antibodies may affect myogenesis largely by blocking
myoblast cell adhesion and/or motility (15, 32, 47, 77). In
contrast, we have not found anti-TM4SF antibodies, or
CD9 overexpression to have an effect on cell adhesion
here or elsewhere (e.g., see references 6, 41, 78). Likewise,
we saw no effect of anti-CD9 or anti-CD81 mAbs on
C2C12 cell motility, despite reports showing TM4SF pro-
teins contributing to the motility of other cell types (2, 31,
49, 75, 78). In conclusion, integrins may associate with
TM4SF proteins and modulate their functions during myo-
genesis, but for the most part their specific functional con-
tributions appear to be very distinct.
Apoptotic Degradation of Myotubes
Aside from CD9 costimulation of T cells leading to apop-
tosis (63), there have been few reports linking TM4SF pro-
teins to apoptosis. Here we used three different methods
to demonstrate that anti-CD9 and anti-CD81 antibodies
promoted apoptotic degradation of C2C12 myotubes after
they were formed. The antibodies did not trigger myoblast
apoptosis. Also, if anti-CD9 and CD81 mAbs were not
added until myoblast fusion had already occurred, they
still resulted in apoptotic degradation. Thus, delayed cell
fusion was not a prerequisite for apoptotic degradation.
Conversely, apoptotic degradation did not contribute to a
delay in cell fusion. The delay in fusion was most obvious
during days 1–3 of differentiation, whereas apoptotic deg-
radation was not obvious at day 3 (see Fig. 3 and Fig. 4 A)
and was not readily detectable until at least day 5.
In previous reports, myotube degradation and apoptosis
in vitro and in vivo were associated with disrupted expres-
sion and localization of integrin a7b1, and loss of adhesion
to laminin-2/4 (42, 68, 69). In vivo muscle cell degradation,
possibly due to diminished cell adhesion, also occurred in
skeletal muscle containing high numbers of cells lacking
a5 (66). However, because neither CD9 nor CD81 appears
to regulate myotube adhesion, or to promote myotube de-
tachment, they must regulate apoptosis by a different
mechanism, perhaps by modulating cell signaling (as dis-
cussed above). Although myoblast precursors may be
more generally susceptible to apoptosis than terminally
differentiated myotubes (70), we did not observe unfused
myoblast apoptosis resulting from anti-CD9 and anti-
CD81 mAb treatment. Thus, TM4SF protein modulation
of apoptosis appears to apply selectively to myotubes, and
not myoblasts.
Other Cell Surface Proteins Involved in Myogenesis
Other cell surface proteins such as N-cadherin, M-cad-
herin, N-CAM, meltrin, VCAM, and CDO have also been
implicated in the process of myoblast fusion (see Introduc-
tion). However, in comparison to CD9 and CD81, pertur-
bation of these other proteins causes not just a delay, but a
more substantial inhibition of myoblast fusion. In addi-
tion, these other proteins have not been linked to apop-
totic degradation of myotubes. Although antibodies to
N-cadherin, a4 integrin, and b1 integrin inhibited myo-
blast fusion, deletion of these genes did not adversely af-
fect muscle formation (13, 27, 76). Thus, contributions of
each of these proteins could be compensated by the func-
tions of other related proteins.
It is well established that TM4SF proteins including
CD9, CD63, CD81, CD82, and CD151 can form com-
plexes with each other within cellular membranes (1, 6,
31a). Thus, besides CD9 and CD81, some of these other
TM4SF proteins might possibly also be involved in myo-
blast fusion. However, definitive analysis of the role of
other TM4SF proteins on C2C12 cells will not be readily
achieved until the appropriate antimurine mAbs become
available. It remains to be determined whether deletion of
genes for any TM4SF proteins will have an adverse effect
on myoblast fusion in vivo. In this regard, there were no
abnormal phenotypes at birth in muscular systems of
CD81-deficient mice  (Tsitsikov, E.N., J.C. Gutierrez-
Ramos, and R.S. Geha, unpublished observations). Given
that several different TM4SF proteins may form com-
plexes with each other, it seems highly possible that loss of
one particular TM4SF protein may be compensated by
others.
In conclusion, we have shown that TM4SF proteins CD9
and CD81 may play key roles during myoblast fusion, as
seen in both murine C2C12 cells and human RD cells. Fur-
thermore, CD9 and CD81 may also contribute to the pro-
tection of myotubes from apoptosis.
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